

Ref: EPL/CS/SE/0025/2025**Date:** April 18, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Script Symbol: EMCURE	BSE Limited P J Towers, Dalal Street, Mumbai - 400 001 Scrip Code/Symbol: 544210/ EMCURE
--	--

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Update on USFDA inspection at API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated February 26, 2025, on the inspection conducted by the United States Food & Drug Administration ("USFDA") at our API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, we wish to inform you that the Company has received the Establishment Inspection Report (EIR). The USFDA has classified the inspection of the facility as "Voluntary Action Indicated" (VAI).

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251